Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2022

View Archived Issues

Medshine Discovery identifies new CREBBP and/or p300 inhibitors

Shionogi discovers 5-HT2A receptor antagonists and/or inverse agonists

New galectin-3 inhibitors synthesized at Galecto Biotech

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents G12C mutant GTPase KRAS inhibitors

IDP Discovery Pharma describes new VEGF inhibitors

M2-mAChRs as therapeutic targets for treating substance use disorders

Discovery of a new class of PDE4B inhibitors with activity in adjuvant-induced arthritis model

RAP-103 studies show potential of biphasic function opioid signaling modulators for use in analgesia

Step Pharma's CTPS1 inhibitor STP-938 cleared to enter clinic for T-cell and B-cell lymphomas

Tonix and KEMRI collaborate to advance TNX-801 as vaccine for monkeypox and smallpox

Neuron-like cells are glioblastoma's evil mastermind

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.